Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence-Reference-Cited by-同舟云学术

Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence

Published:2024-06-26 Issue:1 Volume:23 Page:655-673
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Bawa Samuel¹,Wondimu Abrham¹²,Postma Maarten J.¹³⁴⁵,Hutubessy Raymond⁶,van Hulst Marinus¹⁷

Affiliation:

1. Department of Health Sciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands

2. Department of Social and Administrative Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

3. Department of Economics, Econometrics & Finance; Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands

4. Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia

5. Division of Pharmacology and Therapy, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia

6. Research Department, World Health Organization, Geneva, Switzerland

7. Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2024.2367451

Reference40 articles.

1. A benefit-cost analysis of two-dose measles immunization in Canada

2. DeRoeck D, Wang SA. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. Geneva, Switzerland: WHO Library Cataloguing-in-Publication Data; 2014. p. 1‒2.

3. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data

4. Progress Toward Regional Measles Elimination — Worldwide, 2000–2018

5. Progress Toward Regional Measles Elimination — Worldwide, 2000–2020